Pamiparib Monotherapy for Patients With Germline BRCA1/2-Mutated Ovarian Cancer Previously Treated With at Least Two Lines of Chemotherapy: A Multicenter, Open-Label, Phase II Study.

Xiaohua WuJian Qing ZhuJing WangZhong-Qiu LinRutie YinWei SunQi ZhouSongling ZhangDanbo WangHong ShiYunong GaoYi HuangGuiling LiXiuli WangYing ChengGe LouQinglei GaoLi WangXiuping DuMei PanXiyan MuLi LiMiao LiSong MuBeihua Kong

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)

Pamiparib 60 mg BID showed antitumor activity with durable responses in patients with PSOC or PROC with gBRCA mut, and had a manageable safety profile.

Keyphrases

phase ii study
open label
locally advanced
phase ii
clinical trial
phase iii
study protocol
dna repair
double blind
cross sectional
rectal cancer
squamous cell carcinoma
radiation therapy
newly diagnosed
randomized controlled trial
wild type
breast cancer risk
chemotherapy induced